Enrolling By InvitationNCT07521683
A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia
This study evaluates the safety and effectiveness of NS-136 for people with schizophrenia.
Medication studyAges 18–65China
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of NS-136 for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- ShanghaiSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 20, 2025
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 150
- Sponsor
- NeuShen Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07521683
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Shanghai
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of NS-136 for people with schizophrenia.
Who is behind this study?
The study sponsor is NeuShen Therapeutics.
Does this study involve medication?
Yes. The study involves medication, including NS-136.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
